14/05/12
Appointment of VP for Drug Development03/05/12
Senior Appointment30/04/12
Directorate Changes20/03/12
Amendment Holding(s) in Company20/03/12
Amendment Holding(s) in Company14/05/12
Xenetic Biosciences makes 'pivotal' development appointment - update14/05/12
Xenetic Biosciences makes 'pivotal' development appointment03/05/12
Xenetic Biosciences appoints special consultant to drive development of OncoHist candidate30/04/12
Xenetic Biosciences calls Dr Artur Isaev to the board as Igor Nikolaev resigns02/03/12
Xenetic Bioscience's share plan means good news for management is positive for shareholders - SingerPress: Xenetic Biosciences was unchanged despite gossip that Russian state technology firm Rusnano is rumoured to have acquired a strategic... read more
Press: Lipoxen rose after raising GBP14.4m in a placing, partly funded by SynBio - a new Russian company whose majority shareholder will be a... read more
Press: Lipoxen rose on news that Russian nanotechnology company SynBio has acquired shares in a placing at 11p a share and has also been... read more
Singer Capital Markets initiates coverage of Lipoxen with a 41p price target. Analyst Shawn Manning says he expects the biotech to ink... read more
the company announces a development agreement for its vaccine protecting technology with Cambridge Biostability, Cambridge University... read more
07/11/11
We have an exciting line-up of companies at the Proactive Investors One2One Forum in London on Tuesday (November 8), which has attracted an incredible amount of interest. So this is a call to arms. If you haven't signed up now do so soon to avoid disappointment. Appearing are Xenetic Biosciences, African Medical Investments and e-Therapeutics.
04/08/11
Lipoxen has this morning unveiled an acquisition and an agreement with the Russian state-owned nanotechnology investment company that will utterly transform the bio-pharmaceuticals group.
20/09/10
The development of anaemia treatment ErepoXen is progressing well. Its other key product, long-acting insulin SuliXen, remains on track to enter phase II clinical trials in the final quarter of this year.
16/09/10
The innovative bio-pharmaceutical group receives a much-needed injection of cash from American partner Baxter, which gets to appoint its own non-executive director to the Lipoxen board.
01/03/10
Results of the trial are scheduled to be reported early Q3 this year for the anaemia treatment.
16/05/12
This week: Angel spreads its wings, a healthy announcement for Fitbug and Corero secures new business wins14/05/12
COMPANY SNAPSHOT: Range Resources, Continental Coal, Caza Oil & Gas, Goldplat, Ortac Resources, Atlantic Coal08/05/12
This week: Eluma secures an award, ‘Tou’ director changes at TMZ and ASW advances a new acquisition02/03/12
Broker Roundup Part 2 including Goldstone Resources, Xenetic Bioscience, Belvedere Resources, BT, and Talk Talk08/02/12
This week: New energy for Alkane, solid trading update for SSP and Symphony sings to a powerful audience| Date | Director | Trans | Amount | Type | Price(p) | Value (£) | Holding | % |
|---|---|---|---|---|---|---|---|---|
| 23/04/10 | C.W. Hill | BUY | 150,000 | ORD | 6.83 | 10,245 | 1,825,420 | 1.06 |
| 23/04/10 | M.S. Maguire | BUY | 100,000 | ORD | 6.95 | 6,950 | 1,401,362 | 0.82 |
| 01/04/10 | Sir B.M. Richards | TAKE | 1,071,429 | ORD | 7.00 | 75,000 | 2,262,606 | 1.32 |
| 01/04/10 | M.S. Maguire | TAKE | 535,714 | ORD | 7.00 | 37,500 | 1,301,362 | 0.76 |
| 01/04/10 | C.W. Hill | TAKE | 535,714 | ORD | 7.00 | 37,500 | 1,675,420 | 0.97 |
| Date | Type | Turnover | Profit | EPS (p) | Dividend (p) | Currency |
|---|---|---|---|---|---|---|
| 30/06/11 | Interim | 0.06 | -1.28 | -0.72 | 0.00 | GBX |
| 31/12/10 | Full year | 1.57 | -1.93 | -1.13 | 0.00 | GBX |
| 30/06/10 | Interim | 0.08 | -1.54 | -0.94 | 0.00 | GBX |
| 31/12/09 | Full year | 0.47 | -3.63 | -2.47 | 0.00 | GBX |
| 30/06/09 | Interim | 0.41 | -1.43 | -1.14 | 0.00 | GBX |
Copyright © Proactiveinvestors.co.uk, 2012. All Rights Reserved Design & Development: Tehnicom Computers
